Unclaimed brand
Biolexis Therapeutics is developing oral small-molecule therapies for obesity, type 2 diabetes, and cardiometabolic disease. Two Phase I programs targeting GLP-1 and AMPK.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#1B9CD8
Curious Blue
27, 156, 216
199, 78, 48
88, 28, 0, 15
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#14191A
Woodsmoke
20, 25, 26
190, 13, 9
23, 4, 0, 90
Biolexis Therapeutics is a clinical-stage biotechnology company based in Lehi, Utah, developing oral small-molecule treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. Its focus is convenient, once-daily therapies designed to offer strong efficacy with improved tolerability, as well as combinations that address metabolic disease through complementary mechanisms.
The company’s two lead programs have completed Phase I: BLX-7006 is a non-peptide, allosteric GLP-1 receptor agonist, while BLX-0871 is an AMPK activator designed to target a specific muscle-associated complex. Biolexis is also developing a fixed-dose combination of GLP-1 and AMPK therapies. Its discovery platform emphasizes oral drug properties, tolerability, and compatibility with combination treatment from the earliest stages of development.
Biolexis’s founding team brings extensive experience in drug discovery and development. The company shares updates on its clinical programs and scientific research, and invites potential partners to explore collaboration opportunities. Its work aims to expand treatment options for people living with metabolic disease through oral medicines designed for everyday use.
Company type
Privately Held
Year founded
2021
Company size
2-10 employees
The Biolexis name, logos and brand assets are trademarks of Biolexis and its affiliates. Brandfetch isn't affiliated with or endorsed by Biolexis. Their use is subject to Biolexis's brand guidelines.
